
OSE2101 Plus FOLFIRI Meets OS End Point in Advanced PDAC
OSE2101 (Tedopi), an off-the-shelf neoepitope-based therapeutic cancer vaccine, plus chemotherapy has demonstrated positive overall survival (OS) efficacy in the treatment of patients with advanced or metastatic pancreatic ductal adenocarcinoma (PDAC), …